Campbell & Co Investment Adviser’s Indivior Pharmaceuticals INDV Stock Holding History

Campbell & Co Investment Adviser’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.87M	Sell	69,871 -26,208	-27%	-$951K	0.15%	212
2026 Q1	$2.93M	Buy	96,079 +43,205	+82%	+$1.43M	0.17%	179
2025 Q4	$1.9M	Sell	52,874 -908	-2%	-$27.7K	0.09%	347
2025 Q3	$1.3M	Buy	53,782 +1,834	+4%	+$38.4K	0.1%	326
2025 Q2	$768K	Buy	+51,948	New	+$605K	0.05%	618
2025 Q1	–	Sell	-25,391	Closed	-$325K	–	1163
2024 Q4	$325K	Buy	+25,391	New	+$261K	0.03%	822
2024 Q3	–	Sell	-63,521	Closed	-$996K	–	1211
2024 Q2	$996K	Buy	+63,521	New	+$1.15M	0.08%	367
2024 Q1	–	Sell	-37,948	Closed	-$573K	–	1242
2023 Q4	$573K	Buy	37,948 +1,037	+3%	+$18.4K	0.05%	643
2023 Q3	$801K	Buy	+36,911	New	+$842K	0.1%	349

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Campbell & Co Investment Adviser's INDV Position: Q2 2026 in Review

Campbell & Co Investment Adviser reduced its Indivior Pharmaceuticals (INDV) stake by 27% in Q2 2026, selling an estimated $951K and leaving 69,871 shares worth $2.87M. The position accounts for 0.15% of the portfolio, ranked #212.

Campbell & Co Investment Adviser first reported a position in INDV in Q3 2023 and has held it in 9 quarters since. The position peaked at $2.93M in Q1 2026. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Campbell & Co Investment Adviser held 69,871 shares of Indivior Pharmaceuticals worth $2.87M as of Q2 2026.
Campbell & Co Investment Adviser sold 26,208 Indivior Pharmaceuticals shares in Q2 2026, an estimated $951K.
Indivior Pharmaceuticals made up 0.15% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #212 holding.
Campbell & Co Investment Adviser first reported a position in Indivior Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
Campbell & Co Investment Adviser's Indivior Pharmaceuticals position peaked at $2.93M in Q1 2026.
338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.